Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF) is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors.
Hemostemix Inc.
TSXV:HEM
0.13
cad
Volume 9800
Change
-3.85 %
Prev. Close 0.13 cad
OTCQB:HMTXF
0.10
usd
Volume 15450
Change
5.26 %
Prev. Close 0.09 usd
Disclaimer: All stock information on InvestorIntel.com is currently being fed from multiple sources and is updated automatically every 10-minutes. The information on this site is for information purposes only and InvestorIntel Corp. is neither responsible nor liable for the accuracy of this data.
InvestorIntel Features on Hemostemix Inc.
-
Dr. McNorgan Discusses Hemostemix’s Stem Cell Technology and Potential with Elon Musk’s Neuralink
In this InvestorIntel interview, Tracy Weslosky talks with Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Advisory Board Member Dr.…
-
Thomas Smeenk Discusses the Intersection of Hemostemix’s NCP Treatment and Elon Musk’s Neuralink
In this InvestorIntel interview, Tracy Weslosky talks with Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, CEO, and President…
-
Hemostemix Plans to Revolutionize Stem Cell Therapy with Scalable Production and New Sales Goals
Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0) has developed an effective “stem cell therapy” for…
-
Thomas Smeenk provides an update on Hemostemix’s ACP-01 stem cell treatment for heart disease
Peter Clausi interviews Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and CEO Thomas Smeenk about an…
-
Hemostemix adds depth and strength to its scientific bench on the road to commercialization
Since we last covered Hemostemix where they released the promising results of their retrospective study of heart disease…
-
Hemostemix posts promising clinical trial results from heart failure and limb ischemia treatment
Heart failure (HF) is a growing epidemic in the United States, with an estimated 6 million people affected.…
-
Thomas Smeenk of Hemostemix talks about market reaction to successful litigation settlement
In this InvestorIntel interview with host Stephen Lautens, Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and…